Table 3.

pCR rate TNBC patients treated with chemotherapy plus targeted agents

Study	Study design	TNBC n	Treatment	pCR definition	pCR %
Bevacizumab
Gerber et al7	Phase III	323	Epirubicin + cyclophosphamide → docetaxel + bevacizumab	ypT0 ypN0	39
Earl et al121	Phase III	119	Bevacizumab + docetaxel → epirubicin + cyclophosphamide	ypT0/is ypN0	45
Sikov et al122	Phase II	226	Paclitaxel → doxorubicin + cyclophosphamide + bevacizumab	ypT0/is*	59
Guarneri et al124	Phase II	44	Paclitaxel + carboplatin + bevacizumab	ypT0/is ypN0	50
Kim et al125	Phase II	45	Carboplatin + docetaxel + bevacizumab	ypT0/is ypN0	42
Nahleh et al126	Phase II	32	Nab-paclitaxel + bevacizumab → adriamycin + cyclophosphamide	ypT0/is ypN0	59
Mrózek et al127	Phase II	12	Nab-paclitaxel + carboplatin + bevacizumab	ypT0 ypN0	50
PARP-inhibitor
Telli et al113	Phase II	80	Gemcitabine + carboplatin + iniparib§	ypT0/is ypN0	36
Rugo et al114	Phase II	54	Velparib + carboplatin → doxorubicin + cyclophosphamide	ypT0 ypN0	51
Immunotherapy
Schmid et al128	Phase IB	20	Pembrolizumab + nab-paclitaxel → pembrolizumab + doxorubicin + cyclophosphamide ± carboplatin	ypT0/is ypN0	85
Nanda et al129	Phase II	21	Paclitaxel + pembrolizumab → doxorubicin + cyclophosphamide	ypT0/is ypN0	71

^*Note: pCR in breast only;

^§pCR rate in patients treated with six cycles of neoadjuvant treatment.

Abbreviations: TNBC, triple negative breast cancer; pCR, pathological complete response.